Signant and Propeller partner to improve inhaler adherence with sensor

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Catinsyrup)
(Image: Getty/Catinsyrup)

Related tags Signant Health Propeller Health Asthma Copd eCOA Data collection Digital health

The two companies will combine their digital health services to offer clinical trial participants an inhaler equipped with a sensor to analyze patient adherence.

Signant Health announced that it will connect its TrialMax electronic clinical outcome assessment (eCOA) platform to Propeller Health’s inhaler sensor and linked digital health platform. The combined platform will be aimed towards patients living with asthma and chronic obstructive pulmonary disease (COPD).

According to Signant Health, the linked platforms will lead to better patient adherence to inhaled medications by allowing clients to track medication usage.

The offering is targeted at clinical trial sponsors, clinical research organizations (CROs), and academic institutions.

The ability to follow when patients are using an inhaler would allow those connected to the database to determine when symptoms are triggered, as well as how patients are following their treatment plan.

In addition, it could allow researchers to determine how patients’ use of medication relates to their response to treatment, the company stated.

In a previous interview with Outsourcing-Pharma​, Mike Nolte, CEO of Signant Health, told us how its eCOA platform is beneficial for its clients: “The more we can create enhanced visibility for customers to make good investments and decisions and help them measure the experience in the conduct of research, reversing the lens to view this from a patient perspective, the more we see an untapped area to do exciting new things.”

Bill Byrom, the company’s VP of product strategy and innovation, explained that the Propeller’s sensor allows customers to attain this visibility through ‘frictionless’ data collection.

Propeller’s website states that the sensor works with 90% of inhaled medications available on the US market.

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Related suppliers

Follow us

Products

View more

Webinars